Abbreviations: MDS ¼ myelodysplastic syndrome; NR ¼ non-remission; RA ¼ refractory anemia; RAEB ¼ refractory anemia with excess blasts.
Pretransplant iron overload is one of the important predictors for outcome of allo-hematopoietic SCT (allo-HSCT). [1] [2] [3] Recent studies have demonstrated the prognostic impact of elevated serum ferritin on survival and complications following reduced-intensity SCT (RIST). [3] [4] [5] [6] We previously reported a simple scoring system that consisted of serum ferritin and disease status at transplantation for predicting outcome in patients with AML and myelodysplastic syndrome (MDS). 7 In this report, we studied the applicability of the prognostic score to patients who received RIST in our center.
We evaluated the outcome of consecutive 47 patients with acute leukemia or MDS who underwent RIST at Kanagawa Cancer Center between October 2005 and December 2010. Patient characteristics are summarized in Table 1 . A reduced-intensity conditioning regimen was used in patients who were not eligible for a myeloablative regimen because of age 455 years and/or preexisting organ dysfunction. The regimen consisted of fludarabine (25 mg/ m 2 /day for 5 days) and melphalan (70 mg/m 2 /day for 2 days). Low-dose TBI (4 Gy in two fractions) was added in patients undergoing allo-HSCT from unrelated donors or HLA-mismatched related donors. For the prevention of GVHD, patients received CsA (3 mg/kg, continuous intravenous infusion) or tacrolimus (0.03 mg/kg, continuous intravenous infusion) together with short-term MTX, which was given i.v. at a dose of 10 mg/m 2 on day 1 and 7 mg/m 2 on days 3 and 6. The following variables were investigated as predictors of the outcome: age, sex, pretransplant serum ferritin, disease type, disease status at transplantation (first or second CR and refractory anemia were defined as standard risk, whereas all others were defined as high risk), GVHD prophylaxis, donor type and stem cell source, acute GVHD and chronic GVHD. Pretransplant serum ferritin measured within 2 weeks before starting conditioning regimen was categorized as low (o1000 ng/mL) or high (X1000 ng/mL) on the basis of the previous results. 7 The log-rank test was used for comparison of Kaplan-Meier curves, and the Cox regression model was employed for multivariate analyses. Data were analyzed as of 31 March 2011. Statistical analyses were performed with R 2.12.2 software (R Development Core Team, Vienna, Austria).
At a median follow-up of 48.0 months (range, 5.5-61.8 months), 21 patients are alive in remission and 5 with disease. Leukemia relapse was confirmed in 19 patients and 5 received a second allo-HSCT. The cause of death was relapse in 12 patients, infection in 3, acute GVHD in 3, interstitial pneumonitis in 1, multiple organ failure in 1 and unknown in 1. The median value of pretransplant serum ferritin was 800 ng/mL (range: 119-11 500 ng/mL). On univariate analysis, factors associated with worse OS at 2 year included a high ferritin (vs low ferritin: 28 vs 70%, P ¼ 0.015), high disease risk at transplantation (vs standard ; P ¼ 0.003) were also significantly associated with worse 2-year OS on multivariate analysis. Furthermore, the cumulative incidence of relapse was significantly higher in patients with high ferritin than low ferritin levels (60 vs 34%, P ¼ 0.041) and in patients with high rather than standard risk (62 vs 29%, P ¼ 0.003). The cumulative non-relapse mortality (NRM) rate was similar in patients with high ferritin and in those with low ferritin (16 vs 14%, P ¼ 0.9). Pretransplant serum ferritin and disease risk were each assigned a score, and the sum total was tested as a prognostic score based on three risk groups: low (score ¼ 0), intermediate (score ¼ 1) and high (score ¼ 2). The 2-year OS of the low-(n ¼ 16), intermediate-(n ¼ 21) and high-(n ¼ 10) risk groups was 88%, 48% and 0%, respectively (Po0.001; Figure 1 ). The 2-year disease-free survival of these groups was 65%, 37% and 0%, respectively (Po0.001). These results clearly indicated that the combination of serum ferritin and disease risk at transplantation is a significant predictor for survival in patients receiving RIST. Although RIST has been established for patients with old age and/or comorbidities, it is suggested that patients with RIST have lower NRM but higher incidence of leukemia relapse compared with those who received myeloablative allo-HSCT. Therefore, it is thought that disease status at HSCT is more important in patients undergoing RIST. Furthermore, it has been reported that hematopoietic cell transplantation-specific comorbidity index (HCT-CI) has a clinical impact on transplant outcome, 8 and iron overload is associated with a significantly higher HCT-CI. 9 Considering previous reports and our findings, the prognostic score with pretransplant serum ferritin and disease status might be a simple and valuable tool to predict outcome following RIST.
Our study should be interpreted with caution because of retrospective analysis, small number of patients from a single institution and lack of evaluation concerning HCT-CI. In an attempt to extend allo-HSCT to older patients and those with comorbidities, RIST will be increasingly used, as this procedure has lower rates of severe toxicities. Therefore, a combination of pretransplant serum ferritin, which may partly reflect comorbidity, and disease status affecting leukemia relapse after RIST might be a possible predictor in this setting. Further prospective studies to confirm these findings are needed. Letter to the Editor
